Results 201 to 210 of about 214,982 (356)

Glucagon and intravenous glucose tolerance [PDF]

, 1967
R. J. Jarrett
openalex   +1 more source

Making America Healthy Again: Remedies for Robert F. Kennedy Jr.'s Campaign against Chronic Disease

Hastings Center Report, EarlyView.
Abstract Chronic diseases impose enormous health and economic burdens in the United States, especially on marginalized populations, and demand evidence‐based, equity‐focused interventions. To combat chronic disease, the Trump administration established the Make America Healthy Again Commission, chaired by Department of Health and Human Services ...
Lawrence O. Gostin, Alexandra Finch, Peter Lurie   +2 more
wiley   +1 more source

CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination. [PDF]

Diabetes Obes Metab
Pan Q, Ai W, Chen Y, Shen Z, Yang W, Jiang W, Guo S.   +6 more
europepmc   +1 more source

Characterization of the Effects of Arginine and Glucose on Glucagon and Insulin Release from the Perfused Rat Pancreas [PDF]

, 1974
John E. Gerich, M. Arthur Charles, Gerold M. Grodsky   +2 more
openalex   +1 more source

Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes. [PDF]

Sci Rep
Goodman J, Schain M, Di Stefano G, Lupson V, Horn T, Hill M, Manavaki R, Fryer TD, Bumanlag-Amis E, Jalaludeen N, Jermutus L, Johansson E, Heurling K, Haraldsson H, Evans M, Cheriyan J, Johansson L, Ambery P, Wilkinson IB.   +18 more
europepmc   +1 more source

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

iMetaOmics, EarlyView.
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu, Yu An, Yage Du, Zhaoming Cao, Jie Zheng, Jingya Wang, Tingyi Li, Xingen Lei, Yanhui Lu   +8 more
wiley   +1 more source

Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations. [PDF]

Drugs Context
Anderson SL.
europepmc   +1 more source

Discovery of a novel tetrapeptide as glucose homeostasis modulator with bifunctionalities of targeting DPP‐IV and microbiota

iMeta, EarlyView.
AI‐driven and computation‐based high‐throughput methods were developed to mine novel dipeptidyl peptidase IV (DPP‐IV) inhibitory peptides from hemp seed proteins. The identified peptide VAMP demonstrates a glucose‐lowering effect through dual mechanisms: inhibition of DPP‐IV activity and selective promotion of intestinal Akkermansia muciniphila growth.
Haihong Chen, Wei Li, Wei Hu, Junyu Liu, Canyang Zhang, Yi Wang, Chong Zhang, Xizhen Zhang, Shuo Chen, Qixing Nie, Xinhui Xing   +10 more
wiley   +1 more source

Assessing the Knowledge of Diabetic Patients About Glucagon Use in Hypoglycemia: A Cross-Sectional Study in Riyadh, Saudi Arabia. [PDF]

Cureus
Hussien A, Alkharasani AM, Alaboudi ZA, Alkhathran SA, Abu Suliman T, Alanazi AF, Ezzi MI, Almajid GJ, Almutleeg ZH, Msawa MA.   +9 more
europepmc   +1 more source

The Effect of Intravenous Glucagon on Plasma Amino Acids in the Newborn [PDF]

, 1973
Salomon H. Reisner, Jacob V. Aranda, Eleanor Colle, Apostolos Papageorgiou, David Schiff, Charles R. Scriver, Leo Stern   +6 more
openalex   +1 more source